Oroxin B | Hypocretin-2 | Antitumor Agent | AmBeed-信号通路专用抑制剂

Oroxin B/木蝴蝶苷B {[allProObj[0].p_purity_real_show]}

货号：A123867 同义名： Hypocretin-2

Oroxin B 是一种来自黄芩（Scutellaria baicalensis）根的天然产物，能够选择性诱导肿瘤抑制性内质网应激，同时抑制适应性内质网应激，常用于 B 淋巴瘤等肿瘤的研究。

Oroxin B/木蝴蝶苷B 化学结构
CAS号：114482-86-9

Oroxin B/木蝴蝶苷B 3D分子结构
CAS号：114482-86-9

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]}	现货	1周咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

PI3K 亚型比较

PTEN 亚型比较

自噬亚型比较

产品名称	C2β ↓ ↑	p110α ↓ ↑	p110β ↓ ↑	p110γ ↓ ↑	p110δ ↓ ↑	PI3K ↓ ↑	Vps34 ↓ ↑	其他靶点	纯度
A66	+ C2β, IC50: 462 nM	++ p110α, IC50: 32 nM							99%+
Taselisib	+ C2β, IC50: 292 nM	++++ PI3Kα, Ki: 0.29 nM	+++ PI3Kβ, Ki: 9.1 nM	++++ PI3Kγ, Ki: 0.97 nM	++++ PI3Kδ, Ki: 0.12 nM		+ hVps34, IC50: 374 nM		99%+
Gedatolisib		++++ PI3Kα, IC50: 0.4 nM		+++ PI3Kγ, IC50: 5.4 nM				mTOR	99%
HS-173		++++ PI3Kα , IC50: 0.8 nM							99%+
Serabelisib		+++ PI3Kα, IC50: 21 nM							99%+
GNE-477		++++ PI3Kα, IC50: 4 nM						mTOR	99%
YM-201636		+ p110α, IC50: 3.3 μM						PIKfyve	98%
AS-252424		+ PI3Kα, IC50: 935 nM		++ PI3Kγ, IC50: 33 nM					99%
Alpelisib		+++ PI3Kα, IC50: 5 nM							99%+
AS-604850		+ PI3Kα, IC50: 4.5 μM		+ PI3Kγ, IC50: 0.25 μM					99%
SF2523		++ PI3Kα, IC50: 34 nM		++ PI3Kγ, IC50: 158 nM				DNA-PK,mTOR	99%+
Inavolisib		++++ PI3K alpha, IC50: 0.038 nM							99%+
Bimiralisib		++++ PI3Kα, Kd: 1.5 nM	+++ PI3Kβ, Kd: 11 nM	++ PI3Kγ, Kd: 25 nM	++ PI3Kδ, Kd: 25 nM			mTOR	99%+
GSK1059615		++++ PI3Kα, IC50: 0.4 nM	++++ PI3Kβ, IC50: 0.6 nM	+++ PI3Kγ, IC50: 5 nM	++++ PI3Kδ, IC50: 2 nM			mTOR	98%
GSK2636771			✔						99%
Fimepinostat		+++ PI3Kα, IC50: 19 nM	++ PI3Kβ, IC50: 54 nM		++ PI3Kδ, IC50: 39 nM				99%+
VS-5584		++++ PI3Kα, IC50: 2.6 nM	+++ PI3Kβ, IC50: 21 nM	++++ PI3Kγ, IC50: 3.0 nM	++++ PI3Kδ, IC50: 2.7 nM			mTOR	98%
Dactolisib		++++ p110α1, IC50: 4 nM	++ p110β, IC50: 75 nM	+++ p110γ, IC50: 5 nM	+++ p110δ, IC50: 7 nM				98+%
PI-103		++++ p110α, IC50: 2 nM	++++ p110β, IC50: 3 nM	+++ p110γ, IC50: 15 nM	++++ p110δ, IC50: 3 nM			DNA-PK,mTOR	99%+
PI-3065			+ p110β, IC50: 1078 nM		+++ p110δ, IC50: 15 nM				99%+
Voxtalisib		++ PI3Kα, IC50: 39 nM	++ PI3Kβ, IC50: 113 nM	+++ PI3Kγ, IC50: 9 nM	++ PI3Kδ, IC50: 43 nM			DNA-PK,mTOR	99%+
AZD-8835		+++ PI3Kα, IC50: 6.2 nM	+ PI3Kβ, IC50: 431 nM	++ PI3Kγ, IC50: 90 nM	+++ PI3Kδ, IC50: 5.7 nM				99%
Pilaralisib analogue		++ PI3Kα, IC50: 39 nM	++ PI3Kβ, IC50: 36 nM	+++ PI3Kγ, IC50: 23 nM	++ PI3Kδ, IC50: 36 nM				99%+
ZSTK474		+++ PI3Kα, IC50: 16 nM	++ PI3Kβ, IC50: 44 nM	++ PI3Kγ, IC50: 49 nM	+++ PI3Kδ, IC50: 4.6 nM	++ PI3K, IC50: 37 nM			98%
AS-605240		++ PI3Kα, IC50: 60 nM	+ PI3Kβ, IC50: 270 nM	+++ PI3Kγ, IC50: 8 nM	+ PI3Kδ, IC50: 300 nM				98%
TGX-221			+++ p110β, IC50: 5 nM		++ p110δ, IC50: 0.1 μM				99%+
PF-04691502		++++ PI3Kα, Ki: 1.8 nM	++++ PI3Kβ, Ki: 2.1 nM	++++ PI3Kγ, Ki: 1.9 nM	++++ PI3Kδ, Ki: 1.6 nM			mTOR	98+%
GDC-0084		++++ PI3Kα, Ki app: 2 nM	++ PI3Kβ, Ki app: 46 nM	+++ PI3Kγ, Ki app: 10 nM	++++ PI3Kδ, Ki app: 3 nM			mTOR	99%+
Buparlisib		++ p110α, IC50: 52 nM	+ p110β, IC50: 166 nM	+ p110γ, IC50: 262 nM	++ p110δ, IC50: 116 nM		+ Vps34, IC50: 2.4 μM	mTOR	98%
LY294002		+ p110α, IC50: 0.5 μM	+ p110β, IC50: 0.97 μM		+ p110δ, IC50: 0.57 μM			DNA-PK	99%+
AZD 6482		+ PI3Kα, IC50: 870 nM	+++ PI3Kβ, IC50: 10 nM		++ PI3Kδ, IC50: 80 nM			DNA-PK	99%+
Pictilisib		++++ p110α, IC50: 3 nM	++ p110β, IC50: 33 nM	++ p110γ, IC50: 75 nM	++++ p110δ, IC50: 3 nM			mTOR	99%+
PKI-402		++++ PI3Kα, IC50: 2 nM	+++ PI3Kβ, IC50: 7 nM	+++ PI3Kγ, IC50: 16 nM	+++ PI3Kδ, IC50: 14 nM			mTOR	98%
Copanlisib		++++ PI3Kα, IC50: 0.5 nM	++++ PI3Kβ, IC50: 3.7 nM	+++ PI3Kγ, IC50: 6.4 nM	++++ PI3Kδ, IC50: 0.7 nM				99%+
Omipalisib		++++ p110α, Ki: 0.019 nM	++++ p110β, Ki: 0.13 nM	++++ p110γ, Ki: 0.06 nM	++++ p110δ, Ki: 0.024 nM				99%+
Izorlisib		+++ PI3Kα, IC50: 14 nM	++ PI3Kβ, IC50: 0.12 μM	++ PI3Kγ, IC50: 36 nM	+ PI3Kδ, IC50: 0.50 μM				99%+
AZD8186		++ PI3Kα, IC50: 35 nM	++++ PI3Kβ, IC50: 4 nM		+++ PI3Kδ, IC50: 12 nM				99%
KU-0060648		++++ PI3Kα, IC50: 4 nM	++++ PI3Kβ, IC50: 0.5 nM	+ PI3Kγ, IC50: 0.59 μM	++++ PI3Kδ, IC50: 0.1 nM			DNA-PK	98%
Apitolisib		+++ p110α, IC50: 5 nM	++ p110β, IC50: 27 nM	+++ p110γ, IC50: 14 nM	+++ p110δ, IC50: 7 nM			mTOR	98%+
CZC24832			+ PI3Kβ, IC50: 1.1 μM	++ PI3Kγ, IC50: 27 nM					98+%
BGT226 maleate		++++ PI3Kα, IC50: 4 nM	++ PI3Kβ, IC50: 63 nM	++ PI3Kγ, IC50: 38 nM				mTOR	99%+
TG 100713		++ PI3Kα, IC50: 165 nM	+ PI3Kβ, IC50: 215 nM	++ PI3Kγ, IC50: 50 nM	+++ PI3Kδ, IC50: 24 nM				98%+
PI3K-IN-1		++ PI3Kα, IC50: 39 nM	++ PI3Kβ, IC50: 113 nM	+++ PI3Kγ, IC50: 9 nM	++ PI3Kδ, IC50: 43 nM			DNA-PK,mTOR	98+%
TG100-115		+ PI3Kα, IC50: 1.3 μM	+ PI3Kβ, IC50: 1.2 μM	++ PI3Kγ, IC50: 83 nM	+ PI3Kδ, IC50: 235 nM				98%
PIK-90		+++ PI3Kα, IC50: 11 nM	+ PI3Kβ, IC50: 350 nM	+++ PI3Kγ, IC50: 18 nM	++ PI3Kδ, IC50: 58 nM				99%+
PIK-294			+ p110β, IC50: 490 nM	++ p110γ, IC50: 160 nM	+++ p110δ, IC50: 10 nM				99%+
Duvelisib			++++ PI3Kβ, Ki: 1564 pM	++ PI3Kγ, Ki: 243 pM	++++ PI3Kδ, Ki: 23 pM				99%+
GDC-0326		++++ PI3Kα, Ki: 0.2 nM	++ PI3Kβ, Ki: 26.6 nM	+++ PI3Kγ, Ki: 10.2 nM	++++ PI3Kδ, Ki: 4 nM				98%
Quercetin Dihydrate			+ PI3Kβ, IC50: 5.4 μM	+ PI3Kγ, IC50: 2.4 μM	+ PI3Kδ, IC50: 3.0 μM				95%
Quercetin			+ PI3Kβ, IC50: 5.4 μM	+ PI3Kγ, IC50: 2.4 μM	+ PI3Kδ, IC50: 3.0 μM			PKC,Src,Sirtuin	95%
Leniolisib		+ PI3Kα, IC50: 0.244 μM	+ PI3Kβ, IC50: 0.424 μM	+ PI3Kγ, IC50: 2.23 μM	+++ PI3Kδ, IC50: 0.011 μM			DNA-PK	99%+
PIK-108			✔						99%
Eganelisib				+++ PI3Kγ, IC50: 16 nM					99%+
CAY10505				✔					99%
IPI-3063					++++ p110δ, IC50: 2.5 nM				99%
Nemiralisib					++++ PI3Kδ, pKi: 9.9				99%+
PF-4989216		++++ p110α, IC50: 2 nM		++ p110γ, IC50: 65 nM	++++ p110δ, IC50: 1 nM				99%+
PIK-75 HCl		+++ p110α, IC50: 5.8 nM		++ p110γ, IC50: 76 nM	+ p110δ, IC50: 0.51 μM			DNA-PK	99%+
Tenalisib				++ PI3Kγ, IC50: 33.2 nM	++ PI3Kδ, IC50: 24.5 nM				98%
Acalisib					+++ p110δ, IC50: 14 nM				99%+
Umbralisib					+++ PI3Kδ, IC50: 22.2 nM				99%+
AMG319				+ PI3Kγ, IC50: 850 nM	+++ PI3Kδ, IC50: 18 nM				99%
IC-87114				+ PI3Kγ, IC50: 29 μM	+ PI3Kδ, IC50: 0.5 μM				99%+
Idelalisib				++ p110γ, IC50: 89 nM	++++ p110δ, IC50: 2.5 nM				98%
PIK-293				+ p110γ, IC50: 10 μM	+ p110δ, IC50: 0.24 μM				99%+
Vps34-PIK-III					+ PI3Kδ, IC50: 1.2μM		+++ Vps34, IC50: 0.018μM		99%+
GSK2292767					✔				98%
Seletalisib				+ PI3Kγ, IC50: 282 nM	+++ PI3Kδ, IC50: 12 nM				99%+
P110δ-IN-1					++++ P110δ, IC50: 0.6 nM				99%
PI3Kδ-IN-5					++++ PI3Kδ, IC50: 0.9 nM				99%
SRX3207		+ PI3K alpha, IC50: 244 nM		+ PI3K gamma, IC50: 9790 nM	+ PI3K delta, IC50: 388 nM			Syk	98%
Parsaclisib HCl					++++ PI3Kδ, IC50: 1 nM				98%
IHMT-PI3Kδ-372					+++ PI3Kδ, IC50: 14 nM				98%
Trigonelline						✔		Akt	99%+
Wortmannin						++++ PI3K, IC50: 3 nM		DNA-PK,MLCK	99%+
Samotolisib						✔		DNA-PK	99%+
GNE-317						✔			99%+
Oroxin B						✔		Akt,PTEN	99%+
NU 7026						+ PI3K, IC50: 13 μM		DNA-PK	98+%
Deguelin						✔		Akt	99%+
Ailanthone						✔		ATM/ATR,Akt,CDK	98%
Resibufogenin						✔		ROS	98%
KU-57788						+ PI3K, IC50: 5 μM		DNA-PK,mTOR	99%+
Cinobufagine						✔		Akt	99%
α-Linolenic acid						✔			97% (GC)
MTX-211						✔		EGFR	98%
PI3K/mTOR Inhibitor-2						++++ PI3K, IC50: 3.4 nM		mTOR	99%+
SPP-86						✔			99%+
(E)-Akt inhibitor-IV						✔			98%
Vps34-IN-1							++ Vps34, IC50: 25 nM		98%
SAR405							++++ Vps34, IC50: 1.2 nM		98+%
3-Methyladenine				+ PI3Kγ, IC50: 60 μM			+ Vps34, IC50: 25 μM	Autophagy	98%
Vps34-IN-4							+++ VPS34, IC50: 15 nM		98%+
Autophinib							+++ Vps34, IC50: 19 nM	Autophagy	99%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	PTEN ↓ ↑	纯度
VO-Ohpic trihydrate	+++ PTEN, IC50: 35 nM	98%
SF1670	++ PTEN, IC50: 2 μM	99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	Autophagy ↓ ↑	其他靶点	纯度
SBI-0206965	+++ ULK2, IC50: 711 nM ULK1, IC50: 108 nM		95%
Hydroxychloroquine sulfate	✔		99%
Valproic acid sodium	✔	HDAC	97%
PFK-015	++ PFKFB3, IC50: 207 nM		99%+
MRT68921 HCl	++++ ULK2, IC50: 1.1 nM ULK1, IC50: 2.9 nM		99%+
ROC-325	✔		99%+
Autophinib	+++ Autophagy, IC50: 40 nM		99%
Lys05	✔		99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Oroxin B/木蝴蝶苷B 生物活性

靶点

PI3K

描述

Oroxin B, a natural product isolated and purified from the roots of Scutellaria baicalensis., can selectively induce tumor-suppressive ER stress and concurrently inhibit tumor-adaptive ER stress in B-lymphoma cells for effective anti-lymphoma therapy.

Oroxin B/木蝴蝶苷B 细胞实验

Cell Line Bone marrow-derived macrophages (BMM) Bone marrow-derived macrophages (BMM) HepG2 cells Primary mice chondrocytes Human hepatoma cell line SMMC-7721 HepG2 cells	Concentration	Treated Time	Description	References
Bone marrow-derived macrophages (BMM)	50μM	1-3 days or 3-5 days	Investigate the time-dependent effect of OB on RANKL-induced osteoclast formation, results showed that early addition of OB significantly reduced osteoclast formation	Drug Des Devel Ther. 2021 Nov 30;15:4811-4825.
Bone marrow-derived macrophages (BMM)	10μM, 20μM, 30μM, 40μM, 50μM	1, 3, 5, 7 days	Evaluate the cytotoxic effects of OB on BMMs, results showed that OB concentration up to 50μM had no negative effect on BMMs proliferation	Drug Des Devel Ther. 2021 Nov 30;15:4811-4825.
HepG2 cells	0.2, 0.4, 0.6 mg/mL	24 hours	To evaluate the effect of Oroxin B on the proliferation of HepG2 cells, the results showed that the apoptosis and necrosis rates of cells in the OB-treated groups were significantly higher than those in the control group.	Molecules. 2019 Nov 30;24(23):4384.
Primary mice chondrocytes	160 µM	24 hours	OB reversed the expression level of anabolic-related proteins (Aggrecan and Collagen II) in IL-1β-induced chondrocytes.	Front Endocrinol (Lausanne). 2022 Dec 1;13:1060721.
Human hepatoma cell line SMMC-7721	0.34, 1.01, 1.68 µM	48 hours	OB inhibited the proliferation of SMMC-7721 cells in a dose-dependent manner and induced apoptosis.	Pharmacogn Mag. 2018 Apr-Jun;14(54):207-213.
HepG2 cells	200 mg/ml	12 h	To evaluate the role of SR-A3 in fatty liver disease, results showed a significant reduction in Sr-a3 mRNA expression in HepG2 cells treated with OA and PA	Nat Commun. 2025 Mar 11;16(1):2430.

Cell Line

Bone marrow-derived macrophages (BMM) Bone marrow-derived macrophages (BMM) HepG2 cells Primary mice chondrocytes Human hepatoma cell line SMMC-7721 HepG2 cells

Concentration

Treated Time

Description

References

Bone marrow-derived macrophages (BMM)

50μM

1-3 days or 3-5 days

Investigate the time-dependent effect of OB on RANKL-induced osteoclast formation, results showed that early addition of OB significantly reduced osteoclast formation

Drug Des Devel Ther. 2021 Nov 30;15:4811-4825.

Bone marrow-derived macrophages (BMM)

10μM, 20μM, 30μM, 40μM, 50μM

1, 3, 5, 7 days

Evaluate the cytotoxic effects of OB on BMMs, results showed that OB concentration up to 50μM had no negative effect on BMMs proliferation

Drug Des Devel Ther. 2021 Nov 30;15:4811-4825.

HepG2 cells

0.2, 0.4, 0.6 mg/mL

24 hours

To evaluate the effect of Oroxin B on the proliferation of HepG2 cells, the results showed that the apoptosis and necrosis rates of cells in the OB-treated groups were significantly higher than those in the control group.

Molecules. 2019 Nov 30;24(23):4384.

Primary mice chondrocytes

160 µM

24 hours

OB reversed the expression level of anabolic-related proteins (Aggrecan and Collagen II) in IL-1β-induced chondrocytes.

Front Endocrinol (Lausanne). 2022 Dec 1;13:1060721.

Human hepatoma cell line SMMC-7721

0.34, 1.01, 1.68 µM

48 hours

OB inhibited the proliferation of SMMC-7721 cells in a dose-dependent manner and induced apoptosis.

Pharmacogn Mag. 2018 Apr-Jun;14(54):207-213.

HepG2 cells

200 mg/ml

12 h

To evaluate the role of SR-A3 in fatty liver disease, results showed a significant reduction in Sr-a3 mRNA expression in HepG2 cells treated with OA and PA

Nat Commun. 2025 Mar 11;16(1):2430.

Oroxin B/木蝴蝶苷B 动物实验

Species Hamsters C57BL/6 mice SD rats C57BL/6 male mice Sprague-Dawley (SD) rats	Animal Model HFHCD-induced MAFLD model Ovariectomized model DEN-induced liver cancer model Destabilized medial meniscus (DMM)-induced osteoarthritis model Rat metabolic study model	Administration	Dosage	Frequency	Description	References
Hamsters	HFHCD-induced MAFLD model	Oral gavage	30 mg/kg	Daily for 4 weeks	To evaluate the therapeutic effect of PTEN agonist Oroxin B on fatty liver, results showed Oroxin B partially reversed the metabolic abnormalities caused by SR-A3 deficiency	Nat Commun. 2025 Mar 11;16(1):2430.
C57BL/6 mice	Ovariectomized model	Intraperitoneal injection	40 mg/kg	Every 2 days for 6 weeks	Verify the protective effect of OB on ovariectomy-induced bone loss, results showed that OB treatment significantly reduced bone loss and osteoclast number	Drug Des Devel Ther. 2021 Nov 30;15:4811-4825.
SD rats	DEN-induced liver cancer model	Oral	4, 12, 24 mg/kg body weight/day	Once daily for 16 weeks	To evaluate the anti-tumor effect of Oroxin B on the DEN-induced liver cancer model, the results showed that OB significantly reduced the number of liver nodules, improved liver histopathological structure, and decreased the levels of AFP and ALT in serum.	Molecules. 2019 Nov 30;24(23):4384.
C57BL/6 male mice	Destabilized medial meniscus (DMM)-induced osteoarthritis model	Intra-articular injection	160 mM	Twice a week for 8 weeks	OB attenuated the cartilage degradation, as well as reversed the expression level of anabolic and catabolic-related proteins such as Aggrecan, Collagen II, and MMP13 induced in DMM-induced OA models.	Front Endocrinol (Lausanne). 2022 Dec 1;13:1060721.
Sprague-Dawley (SD) rats	Rat metabolic study model	Oral	1.24 mg/mL，15 mL/kg	Single dose	Study the pharmacokinetics and metabolites of Oroxin B in rats	Heliyon. 2024 Jun 19;10(12):e33234

Species

Hamsters C57BL/6 mice SD rats C57BL/6 male mice Sprague-Dawley (SD) rats

Animal Model

HFHCD-induced MAFLD model Ovariectomized model DEN-induced liver cancer model Destabilized medial meniscus (DMM)-induced osteoarthritis model Rat metabolic study model

Administration

Dosage

Frequency

Description

References

Hamsters

HFHCD-induced MAFLD model

Oral gavage

30 mg/kg

Daily for 4 weeks

To evaluate the therapeutic effect of PTEN agonist Oroxin B on fatty liver, results showed Oroxin B partially reversed the metabolic abnormalities caused by SR-A3 deficiency

Nat Commun. 2025 Mar 11;16(1):2430.

C57BL/6 mice

Ovariectomized model

Intraperitoneal injection

40 mg/kg

Every 2 days for 6 weeks

Verify the protective effect of OB on ovariectomy-induced bone loss, results showed that OB treatment significantly reduced bone loss and osteoclast number

Drug Des Devel Ther. 2021 Nov 30;15:4811-4825.

SD rats

DEN-induced liver cancer model

Oral

4, 12, 24 mg/kg body weight/day

Once daily for 16 weeks

To evaluate the anti-tumor effect of Oroxin B on the DEN-induced liver cancer model, the results showed that OB significantly reduced the number of liver nodules, improved liver histopathological structure, and decreased the levels of AFP and ALT in serum.

Molecules. 2019 Nov 30;24(23):4384.

C57BL/6 male mice

Destabilized medial meniscus (DMM)-induced osteoarthritis model

Intra-articular injection

160 mM

Twice a week for 8 weeks

OB attenuated the cartilage degradation, as well as reversed the expression level of anabolic and catabolic-related proteins such as Aggrecan, Collagen II, and MMP13 induced in DMM-induced OA models.

Front Endocrinol (Lausanne). 2022 Dec 1;13:1060721.

Sprague-Dawley (SD) rats

Rat metabolic study model

Oral

1.24 mg/mL，15 mL/kg

Single dose

Study the pharmacokinetics and metabolites of Oroxin B in rats

Heliyon. 2024 Jun 19;10(12):e33234

Oroxin B/木蝴蝶苷B 参考文献

Oroxin B/木蝴蝶苷B 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

1.68mL

0.34mL

0.17mL

8.41mL

1.68mL

0.84mL

16.82mL

3.36mL

1.68mL

Oroxin B/木蝴蝶苷B 技术信息

CAS号	114482-86-9
分子式	C₂₇H₃₀O₁₅
分子量	594.52
SMILES Code	O=C1C=C(C2=CC=CC=C2)OC3=C1C(O)=C(O)C(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]5[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O5)O4)=C3
MDL No.	MFCD22125002

别名	Hypocretin-2
运输	蓝冰

存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Sealed in dry, 2-8°C

溶解方案

细胞实验：

DMSO: 105 mg/mL(176.61 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验：请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用；以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

方案二

Oroxin B/木蝴蝶苷B {[allProObj[0].p_purity_real_show]}

Oroxin B/木蝴蝶苷B 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Oroxin B/木蝴蝶苷B 质控信息

Oroxin B/木蝴蝶苷B 生物活性

Oroxin B/木蝴蝶苷B 细胞实验

Oroxin B/木蝴蝶苷B 动物实验

Oroxin B/木蝴蝶苷B 参考文献

Oroxin B/木蝴蝶苷B 实验方案

Oroxin B/木蝴蝶苷B 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Oroxin B/木蝴蝶苷B {[allProObj[0].p_purity_real_show]}

Oroxin B/木蝴蝶苷B 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Oroxin B/木蝴蝶苷B 质控信息

Oroxin B/木蝴蝶苷B 生物活性

Oroxin B/木蝴蝶苷B 细胞实验

Oroxin B/木蝴蝶苷B 动物实验

Oroxin B/木蝴蝶苷B 参考文献

Oroxin B/木蝴蝶苷B 实验方案

Oroxin B/木蝴蝶苷B 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Oroxin B/木蝴蝶苷B 纯度/质量文件产品仅供科研